UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficient metal ion sieving in rectifying subnanochannels enabled by metal–organic frameworks

Nature materials, 2020-07, Vol.19 (7), p.767-774

2020

Volltextzugriff (PDF)

Fast and selective fluoride ion conduction in sub-1-nanometer metal-organic framework channels

Nature communications, 2019-06, Vol.10 (1), p.2490-12, Article 2490

2019

Volltextzugriff (PDF)

MKL1-induced lncRNA SNHG18 drives the growth and metastasis of non-small cell lung cancer via the miR-211-5p/BRD4 axis

Cell death & disease, 2021-01, Vol.12 (1), p.128-128, Article 128

2021

Volltextzugriff (PDF)

Pyrotinib in HER2 -Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study

Journal of clinical oncology, 2020-08, Vol.38 (24), p.2753-2761

2020

Volltextzugriff (PDF)

LncRNA LINC00173 enhances triple-negative breast cancer progression by suppressing miR-490-3p expression

Biomedicine & pharmacotherapy, 2020-05, Vol.125, p.109987, Article 109987

2020

Volltextzugriff (PDF)

Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data

BMC cancer, 2024-02, Vol.24 (1), p.178-178, Article 178

2024

Volltextzugriff (PDF)

Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study

BMC pulmonary medicine, 2023-05, Vol.23 (1), p.175-175, Article 175

2023

Volltextzugriff (PDF)

Association of PD-L1 expression and clinical outcomes in ROS1 - rearranged advanced non-small cell lung cancer treated with crizotinib

Frontiers in oncology, 2024-05, Vol.14, p.1405683-1405683

2024

Volltextzugriff (PDF)

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective

Frontiers in oncology, 2022-03, Vol.12, p.863043

2022

Volltextzugriff (PDF)

Construction of angstrom-scale ion channels with versatile pore configurations and sizes by metal-organic frameworks

Nature communications, 2023-01, Vol.14 (1), p.286-286, Article 286

2023

Volltextzugriff (PDF)

Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6

Cancer cell international, 2020-12, Vol.20 (1), p.574-574, Article 574

2020

Volltextzugriff (PDF)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

BMC cancer, 2021-11, Vol.21 (1), p.1215-1215, Article 1215

2021

Volltextzugriff (PDF)

Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study

Frontiers in oncology, 2024-07, Vol.14, p.1391828

2024

Volltextzugriff (PDF)

Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience

Frontiers in oncology, 2024-06, Vol.14, p.1412472

2024

Volltextzugriff (PDF)

The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience

Frontiers in oncology, 2024-02, Vol.14, p.1331128-1331128

2024

Volltextzugriff (PDF)

Attention-Based Gated Convolutional Neural Networks for Distant Supervised Relation Extraction

Chinese Computational Linguistics, p.246-257

Volltextzugriff (PDF)

Carbon Nanotube Networks as Nanoscaffolds for Fabricating Ultrathin Carbon Molecular Sieve Membranes

ACS applied materials & interfaces, 2018-06, Vol.10 (23), p.20182-20188

2018

Volltextzugriff (PDF)

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC

International journal of cancer, 2019-06, Vol.144 (11), p.2677-2682

2019

Volltextzugriff (PDF)

Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review

Frontiers in pharmacology, 2023-08, Vol.14

2023

Volltextzugriff (PDF)

Efficacy of chemo-immunotherapy in metastatic BRAF -mutated lung cancer: a single-center retrospective data

Frontiers in oncology, 2024, Vol.14, p.1353491-1353491

2024

Volltextzugriff (PDF)

A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer

Scientific reports, 2024-02, Vol.14 (1), p.3598-3598, Article 3598

2024

Volltextzugriff (PDF)

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

BMC medicine, 2023-01, Vol.21 (1), p.11-13, Article 11

2023

Volltextzugriff (PDF)

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

Molecular cancer, 2022-01, Vol.21 (1), p.4-4, Article 4

2022

Volltextzugriff (PDF)

Case report: The effect of second-line vebreltinib treatment on a patient with advanced NSCLC harboring the MET exon 14 skipping mutation after tepotinib treatment

Frontiers in oncology, 2024-04, Vol.14, p.1331387

2024

Volltextzugriff (PDF)

LINC01089 functions as a ceRNA for miR-152-3p to inhibit non-small lung cancer progression through regulating PTEN

Cancer cell international, 2021-03, Vol.21 (1), p.143-143

2021

Volltextzugriff (PDF)

1 – 25 von 400

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(362)
Mit Volltextzugriff
(365)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(253)
Life Sciences & Biomedicine
(134)
Physical Sciences
(81)
Technology
(73)
Oncology
(57)
Chemistry
(53)
Humans
(53)
Engineering
(37)
Lung Cancer
(30)
Animals
(29)
Chemotherapy
(27)
Materials Science
(27)
Mutation
(25)
Science & Technology - Other Topics
(25)
Female
(24)
Engineering, Chemical
(23)
Lung Neoplasms - Drug Therapy
(23)
Materials Science, Multidisciplinary
(22)
Chemistry, Multidisciplinary
(21)
Tumors
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Efficient metal ion sieving in rectifying subnanochannels enabled by metal–organic frameworks

Fast and selective fluoride ion conduction in sub-1-nanometer metal-organic framework channels

MKL1-induced lncRNA SNHG18 drives the growth and metastasis of non-small cell lung cancer via the miR-211-5p/BRD4 axis

Pyrotinib in HER2 -Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study

LncRNA LINC00173 enhances triple-negative breast cancer progression by suppressing miR-490-3p expression

Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data

Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study

Association of PD-L1 expression and clinical outcomes in ROS1 - rearranged advanced non-small cell lung cancer treated with crizotinib

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective

Construction of angstrom-scale ion channels with versatile pore configurations and sizes by metal-organic frameworks

Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study

Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience

The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience

Attention-Based Gated Convolutional Neural Networks for Distant Supervised Relation Extraction

Carbon Nanotube Networks as Nanoscaffolds for Fabricating Ultrathin Carbon Molecular Sieve Membranes

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC

Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review

Efficacy of chemo-immunotherapy in metastatic BRAF -mutated lung cancer: a single-center retrospective data

A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

Case report: The effect of second-line vebreltinib treatment on a patient with advanced NSCLC harboring the MET exon 14 skipping mutation after tepotinib treatment

LINC01089 functions as a ceRNA for miR-152-3p to inhibit non-small lung cancer progression through regulating PTEN

Suchergebnisse filtern